Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.7.4071

Somatostatin Receptors 3, 4 and 5 Play Important Roles in Gallbladder Cancer  

Guo, Run-Sheng (Department of General Surgery, Jiading Central Hospital)
Shi, Pei-Dong (Department of General Surgery, Jiading Central Hospital)
Zhou, Jie (Department of Ultrasound, Jiading Central Hospital)
Chen, Yue-Yu (Department of General Surgery, Jiading Central Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.7, 2013 , pp. 4071-4075 More about this Journal
Abstract
Expression changes of somatostatin receptor subtypes (SSTRs) including SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 in the development of gallbladder cancer were assessed with attention to relationships with clinical pathological characteristics. SSTRs in 29 gallbladder cancer and 25 normal gallbladder tissue specimens were examined by immunohistochemical staining. Differences between SSTRs expressions and clinical pathological parameters were analyzed by chi-square test. The five subtypes of SSTR were all expressed in gallbladder cancer tissues and SSTR3 presented the highest expression. SSTR5 expression was increased significantly in gallbladder cancer (P<0.05) compared with that in normal gallbladder tissue. SSTR3 expression in highly and moderately differentiated gallbladder cancer was significantly higher than that in poorly differentiated lesions (P<0.05). SSTR4 expression was lower in gallbladder cancer with lymph node metastasis than that in gallbladder cancer without lymph node metastasis (P<0.05). Therfore, these results indicated that SSRT5, SSTR3 and SSTR4 may play important roles in the formation and development of gallbladder cancer.
Keywords
Gallbladder cancer; somatostatin (SST); somatostain receptor (SSTR);
Citations & Related Records
연도 인용수 순위
  • Reference
1 Barbare JC, Bouche O, Bonnetain F, et al (2009). Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer, 45, 1788-97.   DOI   ScienceOn
2 Behr TM, Behe MP (2002). Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med, 32, 97-109.   DOI   ScienceOn
3 Bell GI, Yasuda K, Kong H, et al (1995). Molecular biology of somatostatin receptors. Ciba Found Symp, 190, 65-79; discussion 80-8.
4 Bousquet C, Guillermet J, Vernejoul F, et al (2004). Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis, 36, S2-7.   DOI   ScienceOn
5 Buscail L, Vernejoul F, Faure P, et al (2002). [Regulation of cell proliferation by somatostatin]. Ann Endocrinol (Paris), 63, 2S13-8.
6 Chopra A (2004). 99mTc-Tricarbonyl-K-H-K-H-cholecystokinin 8. in 'Molecular Imaging and Contrast Agent Database (MICAD)': Bethesda (MD).
7 de Aretxabala X, Losada H, Mora J, et al (2004). [Neoadjuvant chemoradiotherapy in gallbladder cancer]. Rev Med Chil, 132, 51-7.
8 de Sa SV, Correa-Giannella ML, Machado MC, et al (2006). Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer, 13, 69-78.   DOI   ScienceOn
9 DeYoung JL, Lien EL (1984). A long-acting injectable dosage form for a somatastatin analog. J Parenter Sci Technol, 38, 234-6.
10 Fiebiger WC, Scheithauer W, Traub T, et al (2002). Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression. Scand J Gastroenterol, 37, 222-5.   DOI
11 Garske U, Sandstrom M, Johansson S, et al (2012). Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol, 51, 86-96.   DOI   ScienceOn
12 Gong W, Qin YY, Li SG, et al (2010). [Somatostatin enhanced anti-tumor effect of doxorubicin on gallbladder cancer cells through the regulation of intracellular drug concentration]. Zhonghua Yi Xue Za Zhi, 90, 2718-22.
13 Gottsmann M, Landgraf R, Londong W, Werder K (1975). [Influence of somatastatin on oral glucose tolerance in autonomous hypersecretion of growth hormone, prolactin or insulin (author's transl)]. Klin Wochenschr, 53, 1161-6.   DOI
14 Hall GH, Turnbull LW, Richmond I, et al (2002). Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. Br J Cancer, 87, 86-90.   DOI   ScienceOn
15 Harada K, Sato Y, Ikeda H, et al (2012). Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs. Virchows Arch, 460, 281-9.   DOI
16 Kaczmarek P, Singh V, Cashen DE, et al (2010). Somatostatin receptor subtypes 2 and 5 mediate inhibition of egg yolk-induced gall bladder emptying in mice. Neurogastroenterol Motil, 22, 204-9, e66.   DOI   ScienceOn
17 Hashimoto K, Masumori N, Tanaka T, et al (2013). Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer. Prostate, 73, 500-11.   DOI   ScienceOn
18 Hofsli E (2002). [The somatostatin receptor family--a window against new diagnosis and therapy of cancer]. Tidsskr Nor Laegeforen, 122, 487-91.
19 Hoyer D, Bell GI, Berelowitz M, et al (1995). Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci, 16, 86-8.   DOI   ScienceOn
20 Kailey B, van de Bunt M, Cheley S, et al (2012). SSTR2 is the functionally dominant somatostatin receptor in human pancreatic beta- and alpha-cells. Am J Physiol Endocrinol Metab, 303, E1107-16.   DOI
21 Kim K, Chie EK, Jang JY, et al (2012). Postoperative chemoradiotherapy for gallbladder cancer. Strahlenther Onkol, 188, 388-92.   DOI   ScienceOn
22 Kouroumalis E, Skordilis P, Thermos K, et al (1998). Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut, 42, 442-7.   DOI   ScienceOn
23 Kuriyama I, Miyazaki A, Tsuda Y, et al (2013). Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase beta. Bioorg Med Chem, 21, 403-11.   DOI   ScienceOn
24 Lamberts SW, van der Lely AJ, Hofland LJ (2002). New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol, 146, 701-5.   DOI   ScienceOn
25 Patel YC (1999). Somatostatin and its receptor family. Front Neuroendocrinol, 20, 157-98.   DOI   ScienceOn
26 Moss CE, Marsh WJ, Parker HE, et al (2012). Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia, 55, 3094-103.   DOI
27 Olias G, Viollet C, Kusserow H, et al (2004). Regulation and function of somatostatin receptors. J Neurochem, 89, 1057-91.   DOI   ScienceOn
28 Patel YC, Greenwood M, Kent G, et al (1993). Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun, 192, 288-94.   DOI   ScienceOn
29 Peverelli E, Busnelli M, Vitali E, et al (2012). Specific roles of Gi protein family members revealed by dissecting somatostatin receptor 5 (SST5) coupling in human pituitary cells. J Cell Sci, 126, 638-44.
30 Pisarek H, Stepien T, Kubiak R, et al (2009). Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res, 2, 1.   DOI   ScienceOn
31 Quan ZW, Yang Y, Li JY, et al (2010). The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation. Biomed Pharmacother, 64, 451-7.   DOI   ScienceOn
32 Reisine T, Bell GI (1995). Molecular biology of somatostatin receptors. Endocr Rev, 16, 427-42.
33 Reubi JC, Schaer JC, Markwalder R, et al (1997). Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med, 70, 471-9.
34 Songgang L, Jiyu L, Gongwei, et al (2009). Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro. Hepatogastroenterology, 56, 1253-60.
35 Ruscica M, Arvigo M, Gatto F, et al (2010). Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol Cell Endocrinol, 315, 254-62.   DOI   ScienceOn
36 Schulz S, Schulz S, Schmitt J, et al (1998). Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtypespecific antibodies. Clin Cancer Res, 4, 2047-52.
37 Seitz S, Buchholz S, Schally AV, et al (2013). Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anticancer Drugs, 24, 150-7.   DOI
38 Susini C, Buscail L (2006). Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol, 17, 1733-42.   DOI   ScienceOn
39 Toumpanakis C, Caplin ME (2013). Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol, 40, 56-68.   DOI   ScienceOn
40 Treglia G, Lococo F, Petrone G, et al (2013). Pulmonary Neuroendocrine Tumor Incidentally Detected by 18F-CH PET/CT. Clin Nucl Med, 38, 196-9.   DOI
41 Valsecchi ME, Coronel M, Intenzo CM, et al (2013). Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. Melanoma Res, 23, 33-9.   DOI